Worth Watching Stocks: Yuma Energy, Inc. (NYSE:YUMA), Chembio Diagnostics, Inc. (NASDAQ:CEMI)


Yuma Energy, Inc. (NYSE:YUMA)

Yuma Energy, Inc. (NYSE:YUMA) represented a move of 0 percent or $0.03 per share and closed its previous day trading session at $0.17. 0 Shares were traded in the last trading session with an Average Volume of 471.4 Million Shares. The stock currently has a Market Capitalization of 4.02 Million.

Yuma Energy, Inc. is an oil and gas company. It focuses on the exploration for, and development of, conventional and unconventional oil and gas prospects, primarily through the use of 3-D seismic surveys in the U. S. Gulf Coast region. The Company operates primarily in Tuscaloosa, Austin Chalk, Frio-Hackberry, and Miocene. It also participates in specific joint ventures with others in the development of oil and gas properties. Yuma Energy, Inc., formerly known as Pyramid Oil Company, is based in Houston, Texas.

The stock traded between $0.160 and $1.830 over 1-Year time period showing its price to sales ratio of 0.18. Yuma Energy, Inc. (NYSE:YUMA) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.

Right now, the stock has a 50-Day Simple Moving Average of $-45.18 and 200-Day Simple Moving Average of $-70.36. Its Price to Free Cash Flow is 0 and Price to Book of 0.16.

Analyst’s recommended the stock as 0 where 1 represents Strong Buy and 5 represents Sell.

Chembio Diagnostics, Inc. (NASDAQ:CEMI)

In the last trading session, Chembio Diagnostics, Inc. (NASDAQ:CEMI) added its value by 0% closing at the price of $6.69. The stock currently has market capitalization of 108.18 Million, with average volume of 92.12 Million shares.

Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Chembio Diagnostics, Inc. (NASDAQ:CEMI) is showing beta of 1.5. This particular value of beta suggests that Chembio Diagnostics, Inc. (NASDAQ:CEMI) has historically moved 150% for every 100% move in the benchmark, based on price level.

EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Chembio Diagnostics, Inc. (NASDAQ:CEMI) is at $-0.5.

The stock currently has RSI of 43.29. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.

CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio’s two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.

Chembio Diagnostics, Inc. (NASDAQ:CEMI) topped its 52-week high price of $11.55 on 08/13/18 and 52-Week Low Price of $ 5.72 on 11/15/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 5.15% and monthly volatility of 7.19% respectively.